Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up

Gastroenterol Clin Biol. 2006 Feb;30(2):247-52. doi: 10.1016/s0399-8320(06)73161-x.


Objectives: To evaluate prescription practices and response to infliximab treatment for Crohn's disease (CD).

Patients and methods: The files of CD patients treated with at least one infusion of infliximab treated in gastroenterology units belonging to university teaching hospitals of the Parisian hospitals group (Assistance Publique-Hôpitaux de Paris (AP-HP) during the year 2000 were analyzed retrospectively.

Results: One hundred and thirty-seven patients (36.0 +/- 12.7 years, 92 females) from 12 centers were studied. Indication for treatment was fistulae or perianal disease in 39% of patients, active Crohn's disease in 45% and mixed conditions in 16%. Mean follow-up was 15.2 +/- 7.2 months. The overall response rate was 85%. No predictive factor of sustained remission could be identified. The mean time to relapse was to 3.9 +/- 3.1 months. Thirty-eight patients were on maintenance therapy at the end of the follow up; 37% exhibiting progressive lost of response to treatment. Immunosuppressive therapy was added to infliximab in 78% of cases but response to infliximab was not modified by addition of immunosuppressive drugs. Adverse events, most frequently minor, were noted in 23% of the patients.

Conclusion: This retrospective study confirms the efficacy and safety of infliximab in CD.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Crohn Disease / drug therapy*
  • Female
  • Follow-Up Studies
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Infliximab
  • Male
  • Retrospective Studies
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Infliximab